Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

Zhou, Ying; Du, Xiyu; Wang, Qianyu; Xiao, Shilin; Zhi, Juan; Gao, Huibin; Yang, Dong

doi:10.1155/2023/3695469

Cited by 5 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Huperzin is a natural compound extracted from the root of Huperzia serrata with anti-inflammatory, antioxidant and antitumor effects. Zhou et al [33] proved by animal experimental studies that thujone glucoside can reduce the expression level of inflammatory factors TNF-α and IL-6, and inhibit the expression of PI3K, AKT, and mTOR proteins in thujone glucoside group of rats, which can prove that thujone glucoside can inhibit the PI3K/ AKT/mTOR pathway in COPD rats, inhibit the inflammation in the airway, and play a protective role against lung injury.…”

Section: Intervention Of Pi3k/akt Signaling Pathway By Tcm In Copd Tc...mentioning

confidence: 99%

Modulation of PI3K/AKT Signaling Pathway by Chinese Medicine Research Progress in Treating Chronic Obstructive Pulmonary Disease

Fei,

Liu,

Liu

et al. 2023

IJPS

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease is a common respiratory disease characterized by persistent respiratory symptoms with incompletely reversible airflow limitation. Currently available treatments include oral or inhaled bronchodilators, oxygen therapy and surgery. However, these treatments are not effective enough in most cases, so it is clinically important to explore the mechanism of action and therapeutic strategies of chronic obstructive pulmonary disease in depth. The phosphatidylinositol 3-kinase/protein kinase B signaling pathway can play an important role in the occurrence and development of chronic obstructive pulmonary disease by regulating the release of inflammatory mediators and oxidative stress. Traditional Chinese medicine is characterized by holistic and comprehensive treatment of diseases, and has achieved good results in the prevention and treatment of chronic obstructive pulmonary disease in recent years. Traditional Chinese medicine monomers, active ingredients and their combinations can directly or indirectly regulate the phosphatidylinositol 3-kinase/protein kinase B signaling pathway by inhibiting the inflammatory response of the airway and alleviating oxidative stress, and play a protective role against chronic obstructive pulmonary disease with their multi-targeting, multi-component, and multi-pathway biologic advantages. Analyzing the research progress of traditional Chinese medicine at home and abroad in recent years, this article reviews the preventive role and mechanism of traditional Chinese medicine in regulating the phosphatidylinositol 3-kinase/protein kinase B signaling pathway in chronic obstructive pulmonary disease, and provides further theoretical basis for the study of the mechanism of clinical prevention and treatment of chronic obstructive pulmonary disease by traditional Chinese medicine.

show abstract

Section: Intervention Of Pi3k/akt Signaling Pathway By Tcm In Copd Tc...mentioning

confidence: 99%

Modulation of PI3K/AKT Signaling Pathway by Chinese Medicine Research Progress in Treating Chronic Obstructive Pulmonary Disease

Fei,

Liu,

Liu

et al. 2023

IJPS

View full text Add to dashboard Cite

show abstract

“…Hypoxemia occurs more frequently during one-lung ventilation, and the degree of ischemia and hypoxia increases as the duration of single lung ventilation exceeds 3 hours. Lung injuries caused by the single lung ventilation can bring secondary harm to patients who have mild-to-moderate abnormal lung function before surgery, and severe cases can eventually develop into acute lung injury ( 11 , 12 ). Moreover, surgical treatment may lead to adverse stress reactions such as activation of inflammatory reactions, limitation of immune functions, and an increase in the risks of tumor recurrence and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Xu¹,

Zhou²,

Maloney³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Surgical resection is the most effective treatment for lung cancer, but it can also lead to adverse stress reactions in the body. The minimization of lung function damage caused by one-lung ventilation and inflammatory reactions caused by surgery are new challenges faced by the field of anesthesiology. Dexmedetomidine (Dex) has been found to be effective in improving perioperative lung function. In this study, we aimed to conduct a systematic review and meta-analysis to examine the effect of Dex on inflammation and pulmonary function after thoracoscopic surgery for lung cancer. Methods A computer-based search was performed to retrieve controlled trials (CTs) about the effects of Dex on inflammation and lung function after thoracoscopic surgery for lung cancer from the databases of PubMed, Embase, Cochrane Library, and Web of Science. The time period for retrieval was set from inception to 1 August 2022. The articles were strictly screened according to the inclusion and exclusion criteria, and data analysis was conducted using the software Stata 15.0. Results A total of 11 CTs were included, involving 1,026 patients overall, with 512 assigned to the Dex group and 514 to the control group. The meta-analysis showed that after Dex treatment, the inflammatory factors of patients with lung cancer who underwent radical resection were all decreased: interleukin-6 (IL-6) [standardized mean difference (SMD) =−2.09; 95% confidence interval (CI): −3.03, −1.14; P=0.003], interleukin-8 (IL-8) (SMD =−1.12; 95% CI: −1.54, −0.71; P=0.001), and tumor necrosis factor-α (TNF-α) (SMD =−2.04; 95% CI: −3.24, 0.84; P=0.001). The pulmonary function of the patients was also improved: forced expiratory volume in the first second (FEV1) (SMD =0.50; 95% CI: 0.24, 0.76; P=0.003), and partial pressure of oxygen (PaO 2 ) (SMD =1.00; 95% CI: 0.40, 1.59; P=0.001). However, there was no significant difference between the two groups regarding adverse reactions [relative risk (RR) =0.68; 95% CI: 0.41, 1.14; P=0.27]. Conclusions In summary, the use of Dex in lung cancer patients after radical surgery can reduce serum inflammatory factors, and this may play an important role in postoperative inflammatory reaction and improving lung function.

show abstract

“…These molecules activate RA-fibroblast-like synoviocytes (RA-FLSs) through regulation of proliferation, migration to synovial tissue, and inflammatory reactions [1]. Dexmedetomidine (Dex), which is known as a pain reliever and activator of the α2-adrenergic receptor (α2-AR), attenuates the cAMP level [4,5] and plays an anti-inflammatory role by inhibiting the NF-κB [6][7][8] and Janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathways [9][10][11]. Dex has been reported to play an inhibitory role in various inflammation-associated diseases, such as RA, and has thus been reviewed [12].…”

Section: Introductionmentioning

confidence: 99%

Multiple-Factors-Induced Rheumatoid Arthritis Synoviocyte Activation Is Attenuated by the α2-Adrenergic Receptor Agonist Dexmedetomidine

Lee

Hong

2023

IJMS

View full text Add to dashboard Cite

Dexmedetomidine (Dex) has analgesic and sedative properties and anti-inflammatory functions. Although the effects of Dex on arthritis have been revealed, the physiological mechanism underlying the interaction between Dex and rheumatoid arthritis (RA)-mediated inflammatory cytokines has not been fully studied. Inflamed and migrated fibroblast-like synoviocytes (FLSs) are involved in RA severity. Thus, we aimed to determine the effects of Dex on RA-FLSs treated with inflammatory cytokines and a growth factor as multiple stimulating inputs. TNF-α, IL-6, and EGF as multiple stimulating inputs increased the cAMP concentration of RA-FLSs, while Dex treatment reduced cAMP concentration. Dex reduced electroneutral sodium-bicarbonate cotransporter 1 (NBCn1) expression, NBC activity, and subsequent RA-FLS migration. The mRNA expression levels of RA-related factors, such as inflammatory cytokines and osteoclastogenesis factors, were enhanced by multiple-input treatment. Notably, Dex effectively reduced these expression levels in RA-FLSs. These results indicate that multiple inflammatory or stimulating inputs enhance RA-FLS migration, and treatment with Dex relieves activated RA-FLSs, suggesting that Dex is a potential therapeutic drug for RA.

show abstract

Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

Cited by 5 publications

References 62 publications

Modulation of PI3K/AKT Signaling Pathway by Chinese Medicine Research Progress in Treating Chronic Obstructive Pulmonary Disease

Modulation of PI3K/AKT Signaling Pathway by Chinese Medicine Research Progress in Treating Chronic Obstructive Pulmonary Disease

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Multiple-Factors-Induced Rheumatoid Arthritis Synoviocyte Activation Is Attenuated by the α2-Adrenergic Receptor Agonist Dexmedetomidine

Contact Info

Product

Resources

About